DoD awards $596M for COVID-19 antigen test kits, raising questions about competition and value

Contract Overview

Contract Amount: $595,940,000 ($595.9M)

Contractor: Siemens Healthcare Diagnostics Inc.

Awarding Agency: Department of Defense

Start Date: 2022-01-21

End Date: 2022-06-25

Contract Duration: 155 days

Daily Burn Rate: $3.8M/day

Competition Type: NOT COMPETED

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 0001 50M COVID-19 ANTIGEN TEST KITS

Place of Performance

Location: CHAMBERSBURG, FRANKLIN County, PENNSYLVANIA, 17201

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Defense obligated $595.9 million to SIEMENS HEALTHCARE DIAGNOSTICS INC. for work described as: 0001 50M COVID-19 ANTIGEN TEST KITS Key points: 1. Significant award for essential medical supplies during a public health crisis. 2. Sole-source nature of the award warrants scrutiny regarding price and alternatives. 3. Contract duration of 155 days suggests a need for rapid deployment. 4. The award represents a substantial investment in diagnostic capabilities. 5. Lack of competition may have limited opportunities for cost savings. 6. Performance metrics and delivery timelines are critical for assessing success.

Value Assessment

Rating: questionable

The $596 million award for COVID-19 antigen test kits is substantial, but without competitive bidding, it's difficult to benchmark its value effectively. The contract's value relative to the number of units (50 million) and the short performance period (155 days) suggests a high per-unit cost. Further analysis would be needed to compare this pricing to other government or commercial procurements of similar diagnostic supplies during the same period to determine if a fair and reasonable price was achieved.

Cost Per Unit: Approximately $11.92 per test kit. This per-unit cost needs to be benchmarked against market rates for similar products during the contract period.

Competition Analysis

Competition Level: sole-source

This contract was awarded on a sole-source basis, meaning only one vendor, Siemens Healthcare Diagnostics Inc., was solicited. This approach is typically used when only one responsible source is available or when there's a compelling urgency. However, the lack of competition means potential savings from a broader bidding process were forgone, and it raises questions about whether alternative suppliers or more competitive pricing could have been secured.

Taxpayer Impact: Taxpayers may have paid a premium due to the absence of competitive pressure. Without a bidding process, there's less assurance that the government secured the best possible price for these critical supplies.

Public Impact

Beneficiaries include military personnel and potentially their families, ensuring readiness and health. Services delivered include the provision of 50 million COVID-19 antigen test kits. Geographic impact is likely nationwide, supporting Department of Defense facilities and personnel. Workforce implications are minimal in terms of direct contract labor, but the availability of tests supports overall workforce health and operational continuity.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Sole-source award limits price discovery and potential savings.
High per-unit cost requires further justification and benchmarking.
Short performance period may indicate rushed procurement, potentially impacting value.
Lack of transparency in the sole-source justification.

Positive Signals

Addresses a critical public health need for diagnostic testing.
Ensures availability of essential supplies for military readiness.
Awarded to a known entity in the diagnostics sector.

Sector Analysis

The procurement falls within the healthcare and life sciences sector, specifically focusing on in-vitro diagnostic substances. The market for COVID-19 testing supplies saw significant volatility and demand surges during the pandemic. This contract represents a substantial portion of the government's investment in diagnostic tools during a critical period. Comparable spending benchmarks would involve analyzing other large-scale government or private sector procurements of antigen tests during 2022.

Small Business Impact

This contract was not set aside for small businesses, nor is there information indicating subcontracting opportunities for small businesses. The sole-source nature further limits the potential for small business participation. The focus was on rapid acquisition of a large quantity of test kits, likely prioritizing established large-scale manufacturers.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Defense's contracting and financial management oversight bodies. Inspector General investigations could be initiated if concerns regarding fraud, waste, or abuse arise. Transparency is limited due to the sole-source nature, but contract award data is publicly available through federal procurement databases.

Related Government Programs

COVID-19 Pandemic Response Contracts
Department of Defense Medical Materiel Procurements
Diagnostic Test Kit Acquisitions
Public Health Emergency Supplies

Risk Flags

Sole-source award
High per-unit cost
Urgent need justification required
Lack of competitive benchmarking

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $595.9 million to SIEMENS HEALTHCARE DIAGNOSTICS INC.. 0001 50M COVID-19 ANTIGEN TEST KITS

Who is the contractor on this award?

The obligated recipient is SIEMENS HEALTHCARE DIAGNOSTICS INC..

Which agency awarded this contract?

Awarding agency: Department of Defense (Department of the Army).

What is the total obligated amount?

The obligated amount is $595.9 million.

What is the period of performance?

Start: 2022-01-21. End: 2022-06-25.

What is the track record of Siemens Healthcare Diagnostics Inc. in fulfilling large-scale government contracts, particularly for medical supplies?

Siemens Healthcare Diagnostics Inc. is a well-established entity in the medical diagnostics field. While specific details on their track record with large-scale government contracts for COVID-19 related supplies are not provided in the abbreviated data, their industry presence suggests experience in manufacturing and distribution. A deeper dive would involve reviewing past performance evaluations, delivery history on similar contracts, and any documented issues or successes in fulfilling government orders. Their ability to scale production rapidly and meet stringent quality standards would be key factors in assessing their suitability for this significant award.

How does the per-unit cost of $11.92 compare to market rates for similar COVID-19 antigen test kits during the contract period?

The per-unit cost of approximately $11.92 for these antigen test kits requires careful benchmarking against market rates prevalent during the contract's performance period (January-June 2022). Market prices for COVID-19 tests fluctuated significantly due to supply and demand dynamics, manufacturing capacity, and the specific type and sensitivity of the test. Without access to detailed market analysis reports or pricing data from comparable government or commercial procurements from that timeframe, it's challenging to definitively state if $11.92 was a competitive price. Factors such as bulk purchasing discounts, specific product features, and urgency of need could influence the final price.

What were the specific justifications for awarding this contract on a sole-source basis?

The provided data indicates the contract was 'NOT COMPETED,' implying a sole-source justification was used. Common reasons for sole-source awards include the unavailability of other sources, urgent and compelling needs where competition is not feasible, or specific technical requirements that only one contractor can meet. For a large quantity of COVID-19 test kits during a public health crisis, an urgent need might have been cited. However, the specific details of this justification, such as the market research conducted to confirm the lack of alternatives or the precise nature of the urgency, are not included in the abbreviated data and would require further investigation into the contract file.

What are the potential risks associated with a sole-source procurement of this magnitude for critical medical supplies?

Sole-source procurements, especially for critical supplies like COVID-19 test kits, carry several risks. Primarily, the absence of competition can lead to higher prices than might be achieved through a competitive bidding process, resulting in less value for taxpayer money. It also reduces the incentive for the sole provider to innovate or offer cost efficiencies. Furthermore, reliance on a single source can create supply chain vulnerabilities; if the contractor faces production issues, delivery delays, or quality control problems, there are no immediate alternative suppliers readily available to fill the gap, potentially impacting public health response efforts.

How does this $596 million award fit into the broader context of federal spending on COVID-19 related medical supplies?

This $596 million award represents a significant, albeit specific, component of the vast federal spending directed towards combating the COVID-19 pandemic. Numerous agencies, including HHS and DoD, allocated substantial funds towards vaccines, therapeutics, testing supplies, personal protective equipment, and other medical necessities. This particular contract for antigen test kits highlights the government's strategy to ensure widespread availability of diagnostic tools to manage the virus's spread and impact. Understanding its place requires comparing it to other large-scale procurements for similar items and assessing how it contributed to the overall national testing strategy and resource allocation during the pandemic.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Solicitation ID: W58P0522R0004

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Siemens Aktiengesellschaft

Address: 511 BENEDICT AVE, TARRYTOWN, NY, 10591

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Foreign Owned, Foreign-Owned and U.S.-Incorporated Business, Manufacturer of Goods, Not Designated a Small Business, Special Designations

Financial Breakdown

Contract Ceiling: $595,940,000

Exercised Options: $595,940,000

Current Obligation: $595,940,000

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Timeline